ZYME

14.91

3.12% -0.48

Handel nachbörslich: 14.91

Zymeworks Inc. (ZYME)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$15.39

Offen:

$15.37

24-Stunden-Volumen:

334.56K

Relative Volume:

0.72

Marktkapitalisierung:

$1.06B

Einnahmen:

$62.71M

Nettoeinkommen (Verlust:

$-112.51M

KGV:

5.325

EPS:

2.8

Netto-Cashflow:

$-96.01M

1W Leistung:

-13.96%

1M Leistung:

+10.61%

6M Leistung:

+63.49%

1J Leistung:

+82.05%

1-Tages-Spanne:

$14.76

$15.40

1-Wochen-Bereich:

$14.76

$17.70

52-Wochen-Spanne:

$7.97

$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Firmenname

Zymeworks Inc.

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

604-678-1388

Adresse

1385 West 8th Avenue, Suite 540, Vancouver, BC

Mitarbeiter

170

Twitter

@ZymeworksInc

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

ZYME's Discussions on Twitter

Vergleichen Sie ZYME mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ZYME	14.91	1.06B	62.71M	-112.51M	-96.01M	2.80
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-03-21	Fortgesetzt	Wells Fargo	Overweight
2023-01-04	Bestätigt	H.C. Wainwright	Neutral
2022-12-20	Hochstufung	Jefferies	Hold → Buy
2022-11-01	Herabstufung	H.C. Wainwright	Buy → Neutral
2022-10-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-10-04	Fortgesetzt	Wells Fargo	Overweight
2022-05-05	Hochstufung	Guggenheim	Neutral → Buy
2022-03-15	Eingeleitet	Evercore ISI	Outperform
2021-12-10	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-17	Fortgesetzt	Guggenheim	Neutral
2021-10-07	Eingeleitet	Jefferies	Hold
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-02-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-02-08	Fortgesetzt	H.C. Wainwright	Buy
2021-01-25	Herabstufung	Citigroup	Buy → Neutral
2020-09-29	Fortgesetzt	JP Morgan	Neutral
2020-08-06	Eingeleitet	SVB Leerink	Outperform
2020-01-10	Eingeleitet	Wolfe Research	Outperform
2019-12-09	Eingeleitet	JP Morgan	Neutral
2019-11-25	Eingeleitet	H.C. Wainwright	Buy
2019-11-20	Eingeleitet	Guggenheim	Buy
2019-09-30	Hochstufung	Raymond James	Outperform → Strong Buy
2019-08-30	Eingeleitet	Stifel	Buy
2019-07-18	Eingeleitet	Deutsche Bank	Buy
2018-05-11	Hochstufung	Barclays	Underweight → Equal Weight
2018-03-19	Eingeleitet	Raymond James	Outperform

Alle ansehen

Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten

Nov 15, 2024

Redmile Group, LLC Adjusts Stake in Zymeworks Inc - GuruFocus.com

Nov 15, 2024

Nov 12, 2024

Zymeworks stock soars to 52-week high, hits $17.29 By Investing.com - Investing.com Australia

Nov 12, 2024

Nov 11, 2024

Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 08, 2024

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking - Simply Wall St

Nov 08, 2024

Zymeworks (NYSE:ZYME) Upgraded to "Strong-Buy" at Leerink Partnrs - MarketBeat

Nov 08, 2024

Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress By Investing.com - Investing.com Nigeria

Nov 07, 2024

Leerink lifts Zymeworks stock target on pipeline progress - Investing.com

Nov 07, 2024

Nov 06, 2024

Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours - Clinical Trials Arena

Nov 06, 2024

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $18.00 - Defense World

Nov 06, 2024

Nov 05, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical - GlobeNewswire

Nov 05, 2024

Zymeworks Launches Phase 1 Trial for ZW191 - TipRanks

Nov 05, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors - The Manila Times

Nov 05, 2024

Zymeworks (NYSE:ZYME) Sets New 52-Week High Following Analyst Upgrade - Defense World

Nov 05, 2024

Nov 04, 2024

Zymeworks stock soars to 52-week high of $14.08 amid robust gains - Investing.com Canada

Nov 04, 2024

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab (NASDAQ:ZYME) - Seeking Alpha

Nov 04, 2024

Zymeworks (NYSE:ZYME) Cut to Equal Weight at Wells Fargo & Company - Defense World

Nov 04, 2024

Zymeworks’ (ZYME) “Neutral” Rating Reiterated at HC Wainwright - Defense World

Nov 04, 2024

Nov 03, 2024

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St

Nov 03, 2024

Wells Fargo Downgrades Zymeworks (ZYME) - MSN

Nov 03, 2024

Zymeworks (NYSE:ZYME) Shares Gap Down – Here’s What Happened - Defense World

Nov 03, 2024

Nov 02, 2024

Zymeworks Inc. (NYSE:ZYME) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024

Zymeworks Q4 2024 Earnings Preview - MSN

Nov 02, 2024

Nov 01, 2024

Zymeworks to Spotlight Innovations at Investor Conferences - MSN

Nov 01, 2024

Earnings call: Zymeworks reports Q3 2024 results and pipeline progress - Investing.com

Nov 01, 2024

Zymeworks (NYSE:ZYME) Shares Gap DownHere's Why - MarketBeat

Nov 01, 2024

Zymeworks stock downgraded at Wells Fargo (ZYME:NASDAQ) - Seeking Alpha

Nov 01, 2024

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook - Simply Wall St

Nov 01, 2024

Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year - Yahoo Finance

Nov 01, 2024

HC Wainwright Reiterates Neutral Rating for Zymeworks (NYSE:ZYME) - MarketBeat

Nov 01, 2024